Table 1.
Baseline characteristics
| Derivation cohort (n = 35) | Validation cohort (n = 123) | p value | |
|---|---|---|---|
| Follow-up (years) |
4.3 ± 1.9 |
3.4 ± 2.3 |
0.02* |
| Age, (years) |
63 ± 18 |
68 ± 16 |
0.12 |
| Male, no (%) |
18 (51) |
60 (49) |
0.70 |
| Comorbidities, no. (%) |
|
|
|
| Atrial fibrillation |
8 (23) |
29 (24) |
1.00 |
| Diabetes |
9 (26) |
25 (20) |
0.49 |
| Heart Failure |
2 (9) |
21 (17) |
0.11 |
| Hypercholesterolemia |
13 (37) |
22 (18) |
0.02* |
| Ischaemic heart disease |
7 (20) |
34 (28) |
0.51 |
| Malignancy |
8 (23) |
18 (15) |
0.13 |
| Stroke |
4 (11) |
3 (2) |
0.04* |
| Charlson’s Comorbidity Index (CCI) Score |
1.5 ± 1.8 |
1.6 ± 1.9 |
0.79 |
| Clinical Outcomes |
|
|
|
| Day 1 PASP, (mmHg) |
33 ± 8 |
41 ± 16 |
0.006* |
| Simplified PESI score |
0.9 ± 0.9 |
0.9 ± 1.0 |
0.88 |
| Recurrent PE, no (%) |
7 (20) |
9 (7) |
0.05 |
| Death, no (%) | 10 (29) | 37 (30) | 1.00 |
Values are presented as mean ± SD or absolute number.
PE Pulmonary embolism, PESI Pulmonary embolism severity index, *p < 0.05.